- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02019680
Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels
Effects of Dietary Blackcurrant Extract and PCSO-524 (PernaCanaliculus Supercritical Oil) on Endothelial Function and Biomarkers of Vascular Health
Background:
- Heart disease is the leading cause of death in the United States. Eating fruits and vegetables with chemicals called flavonoids may protect against heart disease and improve blood flow to the heart. They are found in blackcurrant berries. Oils found in fish and mussels called omega-3 fats have also been shown to protect the heart. Researchers want to know if blackcurrant extract and omega-3 fats can improve blood flow, which may increase blood to the heart. They also want to learn about the health of blood vessels and how the heart works.
Objective:
- To learn if blackcurrant extract and omega-3 fats will improve blood flow and make the heart beat stronger.
Eligibility:
- Healthy adults 55 to 75 years old.
Design:
- Participants will be screened with medical history, physical exam, and blood tests.
- Visit 1 will take 6 7 hours.
- Participants will have physical exam and blood and urine tests.
- A small device like a microphone will be placed on their arm to take pictures of blood vessels. A blood pressure cuff will be tightened on their arm and more pictures will be taken.
- Blood pressure cuffs will be placed on their arms and legs. They will be tightened at the same time and blood pressure will be measured.
- Participants will answer questions about their eating and exercise.
- Every 8 weeks, participants switch from taking blackcurrant and/or omega-3 tablets to a placebo to no tablets. <TAB>
- Every 8 weeks, they will have another shorter clinic visit that will repeat most of visit 1.
Study Overview
Status
Detailed Description
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA
- Men and women between the ages of 55-75 years
- In general good health as determined by screening evaluation
- Normal or pre-hypertensive blood pressure (e.g. Systolic less than or equal to 139 mm Hg and Diastolic less than or equal to 89 mm Hg
- Normal or mild hyperlipidemia (e. g. Total Cholesterol less than or equal to 239, LDL less than or equal to 159, Triglycerides less than or equal to 199, HDL less than or equal to 40 mg/dL)
- BMI between 18.5 to 25 kg/m^2
- Willingness and ability to give consent
- Willingness to make time commitment for the study
EXCLUSION CRITERIA
- Progressive or unstable disease of any body system including cardiovascular, pulmonary, gastrointestinal, central nervous system, psychiatric, endocrine, hematologic, renal or immunologic disorders
- Known acute or chronic inflammatory disease ( e.g. rheumatoid arthritis, systemic lupus erythematosus, hepatitis)
- Elevated C-reactive protein (CRP) level > 3.0 mg/L
- Elevated fasting blood glucose level > 120 mg/dL
- Elevated lipid profile : Total cholesterol > 239 mg/dL, Triglycerides > 200 mg/dL, LDL >160mg/dL
- Abnormal complete blood count (CBC): White Blood Cell Count < 4 or > 10 K/uL, Red Blood Cell Count < 4 or > 7 M/uL, Hemoglobin < 13 or > 18 g/dL, Hematocrit < 39 or > 52%
- Recent or ongoing alcohol or drug abuse (Subjects with moderate alcohol consumption described as 12oz. of beer, 5oz. glasses of wine, or 1.5 glasses of hard liquor/day or greater alcohol consumption will be excluded.)
- Known sensitivity or allergy to fish oil, or shell fish
- Smoking any tobacco products (cigarettes, pipe, etc.)
- Subjects currently taking fish oil supplements (participation is possible after 2 month washout period)
- Subjects taking blood thinners (i.e., Coumadin, warfarin etc.)
- Subjects with bleeding disorders (i.e., hemophilia)
- Subjects taking cholesterol-lowering, anti-hypertensive, thyroid or hormonal medications
- Subjects taking aspirin, non-steroidal anti-inflammatory (NSAIDS) medications or fish oil on a regular basis unless they were discontinued 14 days prior to their first visit.
- Subjects starting cholesterol-lowering, anti-hypertensive, thyroid or hormonal medications or fish oil during the study
- Subjects taking supplements unless they were discontinued 14 days prior to their first visit.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Endothelial function (flow-mediated brachial artery dilation) and arterial stiffness (cardio-ankle vascular index)
Time Frame: 8 weeks x 4
|
8 weeks x 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Biomarkers of vascular health (endothelial dysfunction, inflammation, injury, oxidative stress, nitric oxide status), lipids and fatty acid profile, and flavonoid profiles
Time Frame: 8 weeks x 4
|
8 weeks x 4
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marguerite M Engler, Ph.D., National Institute of Nursing Research (NINR)
Publications and helpful links
General Publications
- Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Colditz G, Ascherio A, Rosner B, Spiegelman D, Willett WC. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 2001 Jun 19;134(12):1106-14. doi: 10.7326/0003-4819-134-12-200106190-00010.
- Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993 Oct 23;342(8878):1007-11. doi: 10.1016/0140-6736(93)92876-u.
- Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol. 1997 Feb;26(1):1-13. doi: 10.1093/ije/26.1.1.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 140034
- 14-NR-0034
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arteriosclerosis
-
Daewoong Pharmaceutical Co. LTD.CompletedArteriosclerosis ObliteransKorea, Republic of
-
Jun-min BaoUnknownArteriosclerosis; ExtremitiesChina
-
Kansai Rosai HospitalAssociation for Establishment of Ebvidence in InterventionsUnknownArteriosclerosis ObliteransJapan
-
GE HealthcareTurku University Hospital; University of Turku; The Finnish Funding Agency for...CompletedArteriosclerosis ObliteransFinland
-
Region Örebro CountyRecruitingCoronary Stenosis | Calcific Coronary ArteriosclerosisSweden
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDUnknownArteriosclerosis ObliteransChina
-
Medtronic CardiovascularCompletedArteriosclerosis of Coronary Artery Bypass GraftCanada, United States
-
Cordis CorporationCompletedCoronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous Coronary | Peripheral ArteriosclerosisUnited States
-
Johns Hopkins UniversityNorthwestern UniversityCompletedCoronary Artery Disease | Coronary Arteriosclerosis | Coronary Atherosclerosis | Atherosclerosis, Coronary | Arteriosclerosis, CoronaryUnited States
-
University of VermontNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Coronary Arteriosclerosis | Cerebrovascular Accident | Cerebral Arteriosclerosis